Theodosia A Kalfa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2598966/publications.pdf

Version: 2024-02-01

117	3,308	172457	161849
papers	citations	29 h-index	54 g-index

119	119	119	5028
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemiaâ€"TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet, The, 2016, 387, 661-670.	13.7	375
2	Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection. Nature, 2013, 504, 158-162.	27.8	338
3	Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature, 2021, 595, 295-302.	27.8	175
4	Erythrocyte NADPH oxidase activity modulated by Rac GTPases, PKC, and plasma cytokines contributes to oxidative stress in sickle cell disease. Blood, 2013, 121, 2099-2107.	1.4	162
5	Rho GTPases in hematopoiesis and hemopathies. Blood, 2010, 115, 936-947.	1.4	142
6	Unrestrained erythroblast development in Nix-/- mice reveals a mechanism for apoptotic modulation of erythropoiesis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6794-6799.	7.1	129
7	Signaling and cytoskeletal requirements in erythroblast enucleation. Blood, 2012, 119, 6118-6127.	1.4	114
8	Novel mechanisms of PIEZO1 dysfunction in hereditary xerocytosis. Blood, 2017, 130, 1845-1856.	1.4	101
9	Rac GTPases regulate the morphology and deformability of the erythrocyte cytoskeleton. Blood, 2006, 108, 3637-3645.	1.4	100
10	Cdc42 critically regulates the balance between myelopoiesis and erythropoiesis. Blood, 2007, 110, 3853-3861.	1.4	88
11	The Voltage-dependent Anion Channel Is a Receptor for Plasminogen Kringle 5 on Human Endothelial Cells. Journal of Biological Chemistry, 2003, 278, 27312-27318.	3.4	86
12	Warm antibody autoimmune hemolytic anemia. Hematology American Society of Hematology Education Program, 2016, 2016, 690-697.	2.5	83
13	Unraveling Macrophage Heterogeneity in Erythroblastic Islands. Frontiers in Immunology, 2017, 8, 1140.	4.8	73
14	Red Blood Cell Dysfunction Induced by High-Fat Diet. Circulation, 2015, 132, 1898-1908.	1.6	71
15	Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. Journal of Clinical Investigation, 2015, 125, 3103-3116.	8.2	62
16	Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen. Haematologica, 2010, 95, 27-35.	3.5	60
17	Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis. Blood Cells, Molecules, and Diseases, 2016, 61, 4-9.	1.4	60
18	Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. American Journal of Hematology, 2019, 94, 149-161.	4.1	55

#	Article	IF	Citations
19	Effects of hydroxyurea treatment for patients with hemoglobin <scp>SC</scp> disease. American Journal of Hematology, 2016, 91, 238-242.	4.1	54
20	Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. American Journal of Hematology, 2019, 94, 871-879.	4.1	51
21	Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19958-19963.	7.1	49
22	Altered phosphorylation of cytoskeleton proteins in sickle red blood cells: The role of protein kinase C, Rac GTPases, and reactive oxygen species. Blood Cells, Molecules, and Diseases, 2010, 45, 41-45.	1.4	49
23	Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the <scp>TW</scp>i<scp>TCH</scp> trial. British Journal of Haematology, 2016, 172, 122-130.	2.5	47
24	Red cell membrane disorders: structure meets function. Blood, 2020, 136, 1250-1261.	1.4	47
25	Inhibition of Band 3 tyrosine phosphorylation: a new mechanism for treatment of sickle cell disease. British Journal of Haematology, 2020, 190, 599-609.	2.5	46
26	The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood, 2008, 111, 1894-1902.	1.4	45
27	Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. Journal of Pediatric Surgery, 2016, 51, 122-127.	1.6	39
28	Gene Targeting RhoA Reveals Its Essential Role in Coordinating Mitochondrial Function and Thymocyte Development. Journal of Immunology, 2014, 193, 5973-5982.	0.8	37
29	Clinical outcomes of splenectomy in children: Report of the splenectomy in congenital hemolytic anemia registry. American Journal of Hematology, 2015, 90, 187-192.	4.1	33
30	The Spectrum of SPTA1-Associated Hereditary Spherocytosis. Frontiers in Physiology, 2019, 10, 815.	2.8	32
31	Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models. Haematologica, 2018, 103, 40-50.	3.5	30
32	K-Cl Cotransporter Gene Expression during Human and Murine Erythroid Differentiation. Journal of Biological Chemistry, 2011, 286, 30492-30503.	3.4	26
33	Cytokinesis failure in RhoA-deficient mouse erythroblasts involves actomyosin and midbody dysregulation and triggers p53 activation. Blood, 2015, 126, 1473-1482.	1.4	26
34	Gene Therapy for Sickle Cell Anemia Using a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant Shows Promising Correction of the Disease Phenotype. Blood, 2018, 132, 1021-1021.	1.4	23
35	Rho GTPases in erythroid maturation. Current Opinion in Hematology, 2014, 21, 165-171.	2.5	22
36	Rare Hereditary Hemolytic Anemias. Hematology/Oncology Clinics of North America, 2019, 33, 373-392.	2.2	22

#	Article	IF	Citations
37	Autoimmune Hemolytic Anemia in the Pediatric Setting. Journal of Clinical Medicine, 2021, 10, 216.	2.4	22
38	VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. American Journal of Human Genetics, 2020, 107, 1149-1156.	6.2	20
39	The impact of the 2009 H1N1 influenza pandemic on pediatric patients with sickle cell disease. Pediatric Blood and Cancer, 2011, 57, 648-653.	1.5	19
40	TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. Blood, 2015, 126, 3-3.	1.4	19
41	Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. Journal of Pharmacology and Experimental Therapeutics, 2022, 380, 210-219.	2.5	18
42	Phylogenetic and Ontogenetic View of Erythroblastic Islands. BioMed Research International, 2015, 2015, 1-8.	1.9	17
43	Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokineticsâ€guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. British Journal of Haematology, 2021, 194, 617-625.	2.5	16
44	Targeting erythroblast-specific apoptosis in experimental anemia. Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 1022-1030.	4.9	14
45	Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumab. British Journal of Haematology, 2016, 175, 744-747.	2.5	14
46	FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease. Blood, 2020, 136, 19-20.	1.4	12
47	Rac GTPases in erythroid biology. Transfusion Clinique Et Biologique, 2010, 17, 126-130.	0.4	11
48	Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FTâ€4202), an Allosteric Activator of Pyruvate Kinaseâ€R, in Healthy Adults: A Randomized, Placeboâ€Controlled, Doubleâ€Blind, Firstâ€inâ€Human Phase 1 Trial. Clinical Pharmacology in Drug Development, 2022, 11, 654-665.	1.6	11
49	Cooperating G6PD mutations associated with severe neonatal hyperbilirubinemia and cholestasis. Pediatric Blood and Cancer, 2011, 56, 840-842.	1.5	8
50	How I approach hereditary hemolytic anemia and splenectomy. Pediatric Blood and Cancer, 2020, 67, e28337.	1.5	8
51	Hereditary xerocytosis: Diagnostic considerations. American Journal of Hematology, 2018, 93, E67-E69.	4.1	7
52	Analysis of Erythropoiesis Using Imaging Flow Cytometry. Methods in Molecular Biology, 2018, 1698, 175-192.	0.9	7
53	Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology, 2021, 12, 636609.	2.8	7
54	Effects of Chronic Transfusion Therapy on MRI and MRA in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Imaging from the Twitch Trial. Blood, 2014, 124, 4052-4052.	1.4	7

#	Article	IF	Citations
55	Diagnosis and clinical management of red cell membrane disorders. Hematology American Society of Hematology Education Program, 2021, 2021, 331-340.	2.5	7
56	Identification of a Murine Erythroblast Subpopulation Enriched in Enucleating Events by Multi-spectral Imaging Flow Cytometry. Journal of Visualized Experiments, 2014, , .	0.3	6
57	Congenital dyserythropoietic anaemia type I diagnosed in a young adult with a history of splenectomy in childhood for presumed haemolytic anaemia. British Journal of Haematology, 2018, 182, 10-10.	2.5	6
58	ER-to-Golgi transport and SEC23-dependent COPII vesicles regulate T cell alloimmunity. Journal of Clinical Investigation, 2021, 131, .	8.2	6
59	Characterizing bulk rigidity of rigid red blood cell populations in sickle-cell disease patients. Scientific Reports, 2021, 11, 7909.	3.3	6
60	Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects. Blood, 2019, 134, 616-616.	1.4	6
61	Pelgerâ€“HuÃ«t anomaly in a child with 1q42.3-44 deletion. Pediatric Blood and Cancer, 2006, 46, 645-648.	1.5	5
62	Longâ€term hematologic and clinical outcomes of splenectomy in children with hereditary spherocytosis and sickle cell disease. Pediatric Blood and Cancer, 2020, 67, e28290.	1.5	5
63	Implementation of nearâ€universal hydroxyurea uptake among children with sickle cell anemia: A singleâ€center experience. Pediatric Blood and Cancer, 2021, 68, e29008.	1.5	5
64	Activation of Pyruvate Kinase-R with Etavopivat (FT-4202) Is Well Tolerated, Improves Anemia, and Decreases Intravascular Hemolysis in Patients with Sickle Cell Disease Treated for up to 12 Weeks. Blood, 2021, 138, 9-9.	1.4	5
65	Alu element insertion inPKLRgene as a novel cause of pyruvate kinase deficiency in Middle Eastern patients. Human Mutation, 2018, 39, 389-393.	2.5	4
66	Peroxiredoxin II (PRDX2) Is a Novel Candidate Gene for Congenital Dyserythropoietic Anemia. Blood, 2018, 132, 3605-3605.	1.4	4
67	Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Blood Cells, Molecules, and Diseases, 2021, 87, 102534.	1.4	3
68	The Novel PIEZO1 Mutation p.L2023V Is Causal for Hereditary Xerocytosis Resulting in Delayed Channel Inactivation and a Dehydrated Red Blood Cell Phenotype. Blood, 2014, 124, 741-741.	1.4	3
69	Iron Unloading By Therapeutic Phlebotomy in Previously Transfused Children with Sickle Cell Anemia: The Twitch Experience. Blood, 2016, 128, 1018-1018.	1.4	3
70	Etavopivat, an Allosteric Activator of Pyruvate Kinase-R, Improves Sickle RBC Functional Health and Survival and Reduces Systemic Markers of Inflammation and Hypercoagulability in Patients with Sickle Cell Disease: An Analysis of Exploratory Studies in a Phase 1 Study. Blood, 2021, 138, 8-8.	1.4	3
71	Anchoring at an island to relieve stress. Blood, 2011, 117, 748-749.	1.4	2
72	Hereditary elliptocytosisâ€associated alphaâ€spectrin mutation p.L155dup as a modifier of sickle cell disease severity. Pediatric Blood and Cancer, 2019, 66, e27531.	1.5	2

#	Article	IF	Citations
73	A painless erythematous swelling of the external ear as a manifestation of Lyme disease: a case report. Journal of Medical Case Reports, 2020, 14, 48.	0.8	2
74	Rasa3 regulates stage-specific cell cycle progression in murine erythropoiesis. Blood Cells, Molecules, and Diseases, 2021, 87, 102524.	1.4	2
75	Altered erythropoiesis in newborns with congenital heart disease. Pediatric Research, 2022, 91, 606-611.	2.3	2
76	Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Blood Cells, Molecules, and Diseases, 2021, 90, 102576.	1.4	2
77	The Spectrum of Alpha-Spectrin Associated Hereditary Spherocytosis. Blood, 2015, 126, 941-941.	1.4	2
78	Compound Heterozygosity of Two Novel JAK2 Mutations in Hereditary Essential Thrombocythemia Implicates Important Monomer-Monomer Interactions in Thrombopoiesis Signaling. Blood, 2016, 128, 3137-3137.	1.4	2
79	Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study. Blood, 2016, 128, 3652-3652.	1.4	2
80	Clinical Application of Massively Parallel Sequencing in the Diagnosis of Hereditary Hemolytic and Dyserythropoietic Anemias. Blood, 2016, 128, 4746-4746.	1.4	2
81	Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease. Blood, 2021, 138, 4162-4162.	1.4	2
82	M-CSF supports medullary erythropoiesis and erythroid iron demand following burn injury through its activity on homeostatic iron recycling. Scientific Reports, 2022, 12, 1235.	3.3	2
83	S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. HemaSphere, 0, 6, 2-2.	2.7	2
84	Autism-associated chromatin remodeler CHD8 regulates erythroblast cytokinesis and fine-tunes the balance of Rho GTPase signaling. Cell Reports, 2022, 40, 111072.	6.4	2
85	Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient. British Journal of Haematology, 2011, 152, 780-783.	2.5	1
86	Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia. Blood, 2018, 132, 507-507.	1.4	1
87	Evaluation of Phenotype-Genotype Correlation in Two Common PIEZO1 Mutations p.R2456H and p.L2495_E2495dup. Blood, 2018, 132, 1040-1040.	1.4	1
88	Alu-Element Insertion in Pklr Gene As a Novel Cause of Severe Hereditary Nonspherocytic Hemolytic Anemia. Blood, 2015, 126, 3349-3349.	1.4	1
89	A Critical Role for the Retinoblastoma Tumor Suppressor Gene in Hematopoietic Stem Cells.. Blood, 2006, 108, 2548-2548.	1.4	1
90	VPS4A : A Novel Candidate Gene for Congenital Dyserythropoietic Anemia. Blood, 2017, 130, 923-923.	1.4	1

#	Article	IF	Citations
91	Angiotensin Signaling Is Essential for Stress Erythropoiesis but Results in Retention of Dysfunctional Mitochondria in Erythrocytes That Generate Excessive Reactive Oxygen Species. Blood, 2020, 136, 31-32.	1.4	1
92	Ex-Vivo FT-4202 Treatment Improves Hemoglobin Oxygen Affinity and Membrane Health in Red Blood Cells of Patients with Hemoglobin SS and Hemoglobin SC Disease Irrespective of Prior Hydroxyurea Use. Blood, 2020, 136, 23-24.	1.4	1
93	Acquired Hemolytic Anemias. , 2019, , 67-79.		0
94	Elevated Reactive Oxygen Species Production In Sickle Erythrocytes Is Modulated by a Pathway Involving Endothelin-1, TGFÎ²1, PKC, and Rac GTPases. Blood, 2010, 116, 1634-1634.	1.4	0
95	Cation Leak in Red Blood Cells of Patients with Wiskott-Aldrich Syndrome Leads to Non-Immunologic Hemolysis. Blood, 2014, 124, 1338-1338.	1.4	0
96	Genotype-Phenotype Correlations in Hereditary Elliptocytosis (HE) and Hereditary Pyropoikilocytosis (HPP). Blood, 2015, 126, 3344-3344.	1.4	0
97	Activation of HIF-2a-EPO Axis in Kidney or Liver Is Sufficient to Drive Erythrocytosis in a Novel Inducible HIF-2a Transgenic Mouse Model. Blood, 2015, 126, 931-931.	1.4	0
98	Unravelling Macrophage Heterogeneity in Erythroblastic Islands Between Species. Blood, 2016, 128, 2436-2436.	1.4	0
99	Reactive Oxygen Species Produced by NADPH Oxidase Contribute to Cardiac Pathology in a Mouse Model of Sickle Cell Disease. Blood, 2016, 128, 853-853.	1.4	0
100	EPO Signaling Triggers Erythrocytosis By Expanding Erythrocytes and Also Subsets of Macrophages. Blood, 2016, 128, 542-542.	1.4	0
101	Treatment of Patients with Severe Congenital Protein C Deficiency in a Registry Study of Protein C Concentrate (Human). Blood, 2016, 128, 2605-2605.	1.4	0
102	Cellular Hydration and Oxidation As Phenotype Modifiers in Sickle Cell Anemia. Blood, 2016, 128, 2446-2446.	1.4	0
103	Rac GTPase. , 2017, , 1-7.		0
104	RGL2 Deficiency Impairs Human Erythropoiesis By Altering Terminal Erythroid Differentiation and Apoptosis. Blood, 2017, 130, 8-8.	1.4	0
105	Rac GTPase. , 2018, , 4408-4414.		0
106	The Erythro-Myeloblastic Island (EMBI): A Hematopoietic Niche Balancing Erythropoiesis and Myelopoiesis. Blood, 2018, 132, 842-842.	1.4	0
107	VPS4A mutations Cause a Syndrome with Dyserythropoiesis, Hemolytic Anemia, and Neurodevelopmental Delay. Blood, 2019, 134, 339-339.	1.4	0
108	Congenital Dyserythropoietic Anemia Type I Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR). Blood, 2019, 134, 3521-3521.	1.4	0

#	Article	IF	Citations
109	Role of Band 3 Tyrosine Phosphorylation in Causing the Vaso-Occlusive Events in Sickle Cell Disease. SSRN Electronic Journal, 0, , .	0.4	0
110	Overexpression of Human TLR8 Causes Fatal Anemia in SLE-Prone Mice By Altering the Bone Marrow Erythropoietic Niche. Blood, 2021, 138, 1989-1989.	1.4	0
111	SERF1 Is Required for G-CSF Resistance of Start-Codon Mutant ELANE Granulocytic Precursors. Blood, 2021, 138, 433-433.	1.4	0
112	Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia. Blood, 2020, 136, 16-17.	1.4	0
113	Increased Hydroxyurea Prescribing Practices over Ten Years with Improved Clinical Outcomes in Children with Sickle Cell Anemia: A Single Center's Experience. Blood, 2020, 136, 34-34.	1.4	0
114	S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS. HemaSphere, 0, 6, 5-5.	2.7	0
115	eP420: Clinical utility of a 38-gene NGS panel in diagnosing patients with hemolytic anemia: A retrospective review of 435 cases. Genetics in Medicine, 2022, 24, S263.	2.4	0
116	Rapid degradation of protein tyrosine phosphatase 1B in sickle cells: Possible contribution to sickle cell membrane weakening. FASEB Journal, 2022, 36, e22360.	0.5	0
117	Insane in the membrane: A case of hereditary spherocytic pyropoikilocytosis. American Journal of Hematology, 2022, 97, 1384-1385.	4.1	0